Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers
Frontiers in Cell and Developmental Biology · 28.05.2026 · 14
DOI: 10.3389/fcell.2026.1812373 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 28.05.2026. Verfasst von Gabriele Saccu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital, Pathology Department, Harvard University, Boston, MA, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 209 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatobiliary cancers are major contributors to cancer-related mortality, mainly due to late-stage diagnosis, poor prognosis, and limited effectiveness of current treatments in advanced disease. Standard therapies comprise surgical resection, liver transplantation, and systemic agents including tyrosine kinase inhibitors and immune checkpoint inhibitors, but their efficacy is often hindered by the development of drug resistance, underlying the urgent need for novel therapeutic strategies. Lipid nanoparticles (LNPs) have emerged as promising delivery vehicles due to their favorable physicochemical properties, enabling the transport of natural biomolecules or engineered drugs for targeted tumor therapy. LNPs are also being explored as platforms for cancer therapy and vaccines. Moreover, recent advances underscore the key role of extracellular vesicles (EVs) in modulating the tumor microenvironment, promoting tumor progression, chemoresistance, and escape from immune recognition and destruction (immune evasion) in hepatobiliary cancers. EVs are being investigated both as biomarkers for early detection and as therapeutic agents, with engineered or drug-loaded EVs showing potential for targeted drug delivery and tissue repair in liver diseases, including cancer. This review highlights the potential of cell-free therapeutic LNP- and EV-based platforms, standalone or in combination, for RNA, small molecules and proteins delivery in improving diagnosis and treatment outcomes in hepatobiliary cancers, in particular, hepatocellular carcinoma and cholangiocarcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boston Children's Hospital, Pathology Department, Harvard University, Boston, MA, United States.
- Institute of Biostructure and Bioimaging (CNR) and Molecular Biotechnology Center "Guido Tarone", Turin, Italy.
Zitieren
APA
Saccu, G., & Fagoonee, S. (2026). Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1812373
Vancouver
Saccu G, Fagoonee S. Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1812373
BibTeX
@article{Saccu2026,
author = {Saccu, Gabriele and Fagoonee, Sharmila},
title = {Lipid nanoparticles and extracellular vesicles: emerging cell free therapeutic platforms for hepatobiliary cancers},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1812373}
}
EUVIMED